Citations

Clear

948 citation(s) found for "Li, Bryan".

Reactivation of Suppressed RhoB is a Critical Step for the Inhibition of Anaplastic Thyroid Cancer Growth
Marlow, Laura A. , Cleland, Alan S., Kurakata, Shinichi, Fujiwara, Kôsaku, Zhang, Ying , Sebo, Thomas, Grant, Clive S., McIver, Bryan, Wadsworth, J. Trad , Smallridge, Robert C., Copland, John A. , Reynolds, Lisa A. , Cooper, Simon JR , Gumz, Michelle L. , Radisky, Derek C. , Marlow, Laura

Mayo Clinic

Cancer Research | February 11, 2009 | Volume: 69 | Issue: 4 | Pages: 1536-1544

10.1158/0008-5472.can-08-3718 | PMID 19208833 Get It

Abstract Anaplastic thyroid carcinoma (ATC) is a highly aggressive form of the disease for which new therapeutic options are desperately needed. Previously, we showed that the high-affinity peroxisome proliferator–activated receptor γ (PPARγ) agonist, RS5444, inhibits cell proliferation of ATC cells via induction of the cyclin-dependent kinase inhibitor p21WAF1/CIP1 (p21). We show here that up-regulation of RhoB is a critical step in PPARγ-mediated activation of p21-induced cell stasis. Using multiple independently derived ATC cell lines, we found that treatment with RS5444 leads to the up-regulation of RhoB and subsequent activation of p21, and that silencing of RhoB by RNAi blocks the ability of RS5444 to induce p21 and to inhibit cell proliferation. Our results show that transcriptional regulation of RhoB by the nuclear transcription factor PPARγ is responsible for the induction of p21 mRNA and protein. We further implicate RhoB as a key signaling effector for the growth inhibition of ATC, as treatment with a histone deacetylase inhibitor shown to increase RhoB expression in lung cancer cells caused the up-regulation of RhoB in ATC cells accompanied by increased expression of p21 and inhibition of cell proliferation; this effect occurred even in ATC cells that were unresponsive to RS5444 due to a lack of expression of PPARγ. Our results implicate RhoB as a novel intermediate in critical signaling pathways and as an additional target for therapeutic intervention in ATC. [Cancer Res 2009;69(4):1536–44]
Case Report: Percutaneous Catheter Management of Persistent Urine Leak due to Iatrogenic Infundibular Stenosis after Partial Nephrectomy
Bruner, Bryan, Ashley, Richard , Leibovich, Bradley C. , Blute, Michael L., LeRoy, Andrew J.

Mayo Clinic

Journal of Endourology | January 2, 2009 | Volume: 23 | Issue: 1 | Pages: 37-42

10.1089/end.2008.0291 | PMID 19118467 Get It

Association of Vascular Endothelial Growth Factor and Vascular Endothelial Growth Factor Receptor-2 Genetic Polymorphisms With Outcome in a Trial of Paclitaxel Compared With Paclitaxel Plus Bevacizumab in Advanced Breast Cancer: ECOG 2100
Schneider, Bryan P. , Wang, Μolin , Radovich, Milan , Thor, Ann D. , Flockhart, David A., Hancock, Bradley A., Davidson, Nancy E. , Perez, Edith A. , Cobleigh, Melody , Shenkier, Tamara, Edgerton, Susan M., Sledge, George W. , Badve, Sunil , Gralow, Julie R. , Dickler, Maura N. , Miller, Kathy D.

Mayo Clinic

Journal of Clinical Oncology | September 29, 2008 | Volume: 26 | Issue: 28 | Pages: 4672-4678

10.1200/jco.2008.16.1612 | PMID 18824714 Get It

Purpose No biomarkers have been identified to predict outcome with the use of an antiangiogenesis agent for cancer. Vascular endothelial growth factor (VEGF) genetic variability has been associated with altered risk of breast cancer and variable promoter activity. Therefore, we evaluated the association of VEGF genotype with efficacy and toxicity in E2100, a phase III study comparing paclitaxel versus paclitaxel plus bevacizumab as initial chemotherapy for metastatic breast cancer. Patients and Methods DNA was extracted from tumor blocks of patients from E2100. Three hundred sixty-three samples were available to evaluate associations between genotype and outcome. Genotyping was performed for selected polymorphisms in VEGF and VEGF receptor 2. Testing for associations between each polymorphism and efficacy and toxicity was performed. Results The VEGF-2578 AA genotype was associated with a superior median overall survival (OS) in the combination arm when compared with the alternate genotypes combined (hazard ratio = 0.58; 95% CI, 0.36 to 0.93; P = .023). The VEGF-1154 A allele also demonstrated a superior median OS with an additive effect of each active allele in the combination arm but not the control arm (hazard ratio = 0.62; 95% CI, 0.46 to 0.83; P = .001). Two additional genotypes, VEGF-634 CC and VEGF-1498 TT, were associated with significantly less grade 3 or 4 hypertension in the combination arm when compared with the alternate genotypes combined (P = .005 and P = .022, respectively). Conclusion Our data support an association between VEGF genotype and median OS as well as grade 3 or 4 hypertension when using bevacizumab in metastatic breast cancer.
Deoxyribonucleic Acid Profiling Analysis of 40 Human Thyroid Cancer Cell Lines Reveals Cross-Contamination Resulting in Cell Line Redundancy and Misidentification
Schweppe, Rebecca E. , Klopper, Joshua , Korch, Christopher , Pugazhenthi, Umarani , Benezra, Miriam , Knauf, Jeffrey A. , Marlow, Laura A. , Copland, John A. , Smallridge, Robert C., Haugen, Bryan R. , Fagin, James A. , Knauf, Jeffrey A , Schweppe, Rebecca E , Marlow, Laura

Mayo Clinic

The Journal of Clinical Endocrinology & Metabolism | August 19, 2008 | Volume: 93 | Issue: 11 | Pages: 4331-4341

10.1210/jc.2008-1102 | PMID 18713817 Get It

Potentially Important Contribution of Dextrose Used as Diluent to Hyperglycemia in Hospitalized Patients
Krajicek, Bryan J. , Kudva, Yogish C. , Hurley, Heather A.

Mayo Clinic

Diabetes Care | March 5, 2007 | Volume: 28 | Issue: 4 | Pages: 981-982

10.2337/diacare.28.4.981 | PMID 15793213 Get It

P4–196: The capacity of persons with very mild to moderate AD to provide informed consent to enroll in a clinical trial
Karlawish, Jason , vanDyck, Christopher, Marson, Daniel , Kim, Scott Y. H. , Knopman, David S. , James, Bryan D.

Mayo Clinic

Alzheimer's & Dementia | August 17, 2006 | Volume: 2 | Issue: 3S_Part_19 | Pages: No page available

10.1016/j.jalz.2006.05.1935 Get It

Nonterminal differentiation represses the neoplastic phenotype in spontaneously and simian virus 40-transformed cells.
Estervig, David N., Tzen, Chin‐Yuan, Minoo, Parviz , Maercklein, Peter B., Hoerl, Bryan J., Scott, R E

Mayo Clinic

Proceedings of the National Academy of Sciences | May 31, 2006 | Volume: 86 | Issue: 5 | Pages: 1652-1656

10.1073/pnas.86.5.1652 | PMID 2537979 Get It

The potential of nonterminal cellular differentiation to stably repress the expression of the neoplastic phenotype of transformed cells is established. Nonterminal differentiation induces spontaneously transformed 3T3 T cells to revert to a nontransformed state and induces the revertant cell clones to become resistant to retransformation by UV irradiation or 4-nitroquinoline oxide treatment. Nonterminal differentiation also induces simian virus 40-transformed 3T3 T cells to repress expression of the large tumor antigen and to revert to a nontransformed state. Although the molecular mechanisms that mediate these and other forms of anticancer activity have not been definitively established, data are presented which suggest that differentiation-induced repression of large tumor antigen expression can be regulated at the level of transcription and/or RNA processing.
Phase I/II Study of Galiximab, an Anti-CD80 Antibody, for Relapsed or Refractory Follicular Lymphoma
Czuczman, Myron S., Thall, Aron D., Younes, Anas , Emmanouilides, Christos, Miller, Thomas P. , Moore, Joseph O., Leonard, John P. , Gordon, Leo I. , Sweetenham, John , Alkuzweny, Baha, Finucane, Deborah M., Leigh, Bryan R., Witzig, Thomas E. , Vose, Julie M. , Gordon, Leo I

Mayo Clinic

Journal of Clinical Oncology | June 30, 2005 | Volume: 23 | Issue: 19 | Pages: 4390-4398

10.1200/jco.2005.09.018 | PMID 15994148 Get It

PurposeThis multicenter, dose-escalation study evaluates the safety, pharmacokinetics, and efficacy of galiximab (anti-CD80 monoclonal antibody) in patients with relapsed or refractory follicular lymphoma.Patients and MethodsPatients had follicular lymphoma that had relapsed or failed to respond to primary therapy; the majority (90%) presented with stage III or IV disease. Four weekly intravenous infusions of galiximab were administered at doses of 125, 250, 375, or 500 mg/m2.ResultsThirty-seven patients received galiximab treatment and were evaluated for safety; 35 were assessable for response. Antibody infusions were safe and well tolerated with no dose-limiting toxicities. A total of 22 (60%) of 37 patients experienced adverse events related to galiximab. All but one of the events were grade 1 or 2; the most common were fatigue, nausea, and headache. Cytopenias were rare; only one patient experienced anemia and febrile neutropenia, which were unrelated to galiximab and resolved after treatment. No patient developed antigaliximab antibody formation. The mean serum half-life ranged from 13 to 24 days. The overall response rate was 11% (two complete responses and two partial responses). Time to best response was delayed (months 3, 6, 9, and 12). Twelve patients (34%) maintained stable disease. Nearly half of all patients (49%) had a decrease in indicator lesions. Two responders remain on study without progression (22 and 24.4 months).ConclusionThe favorable safety profile of galiximab and evidence of single-agent biologic activity and dose-dependent pharmacokinetics support further evaluation of galiximab as a treatment for follicular lymphoma, possibly in combination with other lymphoma therapies.